These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 31904705)
1. Positron Emission Tomography to Characterize Dorsocervical Fat Pad Hypertrophy in People With Treated HIV Infection. Janus SE; Sullivan C; Morrison J; McComsey GA; Longenecker CT J Acquir Immune Defic Syndr; 2020 Mar; 83(3):e23-e25. PubMed ID: 31904705 [No Abstract] [Full Text] [Related]
2. Human immunodeficiency virus treatment-induced adipose tissue pathology and lipoatrophy: prevalence and metabolic consequences. Hammond E; McKinnon E; Nolan D Clin Infect Dis; 2010 Sep; 51(5):591-9. PubMed ID: 20645860 [TBL] [Abstract][Full Text] [Related]
3. Mitochondrial DNA depletion in adipose tissue of HIV-infected patients with peripheral lipoatrophy. Buffet M; Schwarzinger M; Amellal B; Gourlain K; Bui P; Prévot M; Deleuze J; Morini JP; Gorin I; Calvez V; Dupin N J Clin Virol; 2005 May; 33(1):60-4. PubMed ID: 15797366 [TBL] [Abstract][Full Text] [Related]
4. Morphologic and body composition changes are different in men and women on generic combination antiretroviral therapy--an observational study. Padmapriyadarsini C; Swaminathan S; Karthipriya MJ; Narendran G; Menon PA; Thomas BE J Assoc Physicians India; 2010 Jun; 58():375-7. PubMed ID: 21125779 [TBL] [Abstract][Full Text] [Related]
5. Adipose tissue biology and HIV-infection. Giralt M; Domingo P; Villarroya F Best Pract Res Clin Endocrinol Metab; 2011 Jun; 25(3):487-99. PubMed ID: 21663842 [TBL] [Abstract][Full Text] [Related]
6. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. Martin A; Smith DE; Carr A; Ringland C; Amin J; Emery S; Hoy J; Workman C; Doong N; Freund J; Cooper DA; AIDS; 2004 Apr; 18(7):1029-36. PubMed ID: 15096806 [TBL] [Abstract][Full Text] [Related]
7. Perirenal fat diameter measured by echography could be an early predictor of lipodystrophy in HIV type 1-infected patients receiving highly active antiretroviral therapy. Asensi V; Martín-Roces E; Carton JA; Collazos J; Maradona JA; Alonso A; Medina M; Aburto JM; Martínez E; Rojo C; Bustillo E; Fernández C; Arribas JM Clin Infect Dis; 2004 Jul; 39(2):240-7. PubMed ID: 15307034 [TBL] [Abstract][Full Text] [Related]
8. The role of zidovudine in development of lipoatrophy. Moyle GJ AIDS Read; 2005 Nov; 15(11):591-4, 599-600, 603. PubMed ID: 16329181 [No Abstract] [Full Text] [Related]
9. [Effect of anti-retroviral therapy on body composition changes: a literature review]. Dell'Isola C; Aprea L; Pizzella T; Izzo C Infez Med; 2006 Mar; 14(1):5-12. PubMed ID: 16794374 [TBL] [Abstract][Full Text] [Related]
11. Fat Mass Ratio in Brazilian HIV-infected Patients Under Antiretroviral Therapy and Its Relationship With Anthropometric Measurents. Bicudo Bruno Nogueira A; Abreu JM; Mesquita Villela M; Boracini Sanchez AE; Silva Chaves B; Setubal S; Coca Velarde LG; Cruz Filho RAD; Balarini Lima GA; Soares DV J Clin Densitom; 2020; 23(4):623-629. PubMed ID: 30545683 [TBL] [Abstract][Full Text] [Related]
12. Comparison of dorsocervical with abdominal subcutaneous adipose tissue in patients with and without antiretroviral therapy-associated lipodystrophy. Sevastianova K; Sutinen J; Greco D; Sievers M; Salmenkivi K; Perttilä J; Olkkonen VM; Wågsäter D; Lidell ME; Enerbäck S; Eriksson P; Walker UA; Auvinen P; Ristola M; Yki-Järvinen H Diabetes; 2011 Jul; 60(7):1894-900. PubMed ID: 21602514 [TBL] [Abstract][Full Text] [Related]
14. Magnetic resonance imaging evaluation of lipodystrophy in HIV-positive patients receiving highly active antiretroviral therapy. Eichler K; Bickel TM; Klauke S; Eisen J; Vogl TJ; Zangos S Int J STD AIDS; 2015 Jul; 26(8):582-9. PubMed ID: 25139003 [TBL] [Abstract][Full Text] [Related]
15. How much fat loss is needed for lipoatrophy to become clinically evident? Podzamczer D; Ferrer E; Martínez E; Del Rio L; Rosales J; Curto J; Ribera E; Barrufet P; Llibre JM; Aranda M; AIDS Res Hum Retroviruses; 2009 Jun; 25(6):563-7. PubMed ID: 19500014 [TBL] [Abstract][Full Text] [Related]
16. Lipodystrophy and metabolic disorders in HIV-1-infected adults on 4- to 9-year antiretroviral therapy in Senegal: a case-control study. Mercier S; Gueye NF; Cournil A; Fontbonne A; Copin N; Ndiaye I; Dupuy AM; Cames C; Sow PS; Ndoye I; Delaporte E; Simondon KB J Acquir Immune Defic Syndr; 2009 Jun; 51(2):224-30. PubMed ID: 19339897 [TBL] [Abstract][Full Text] [Related]
17. Complications of long-term antiretroviral therapy in HIV-infected children. Prendergast AJ Arch Dis Child; 2013 Apr; 98(4):245-6. PubMed ID: 23413313 [No Abstract] [Full Text] [Related]
18. Objective assessment of facial lipoatrophy changes in a cohort of HIV-infected patients taking combination antiretroviral therapy. Yang Y; Yap M; Oo Tha N; Paton NI HIV Clin Trials; 2008; 9(6):399-406. PubMed ID: 19203905 [TBL] [Abstract][Full Text] [Related]
19. Targets of metabolic toxicity of HIV antiretroviral drugs: the multiple roads to lipodystrophy and metabolic syndrome. Domingo P; Villarroya F Curr Pharm Des; 2010 Oct; 16(30):3337-8. PubMed ID: 20687885 [No Abstract] [Full Text] [Related]
20. [Lipodystrophy in a patient treated with stavudine and didanosine]. Ruel M; Chemlal K; Melchior JC Ann Med Interne (Paris); 1999 Apr; 150(3):269-71. PubMed ID: 10445099 [No Abstract] [Full Text] [Related] [Next] [New Search]